# Dupixent MDL holds first case management conference as docket grows to 38 cases

Attorney advertising. Brief by Lou Schwartz, Schwartz & Associates, PC, Atlanta, Georgia. Published 2026-10-01; updated 2026-10-01. Responsible attorney: Lou Schwartz. Canonical: https://www.snalawyers.com/insights/dupixent-mdl-holds-first-case-management-conference-as-docket-grows-to

U.S. District Judge Zahid N. Quraishi held the initial case management conference on October 1, 2026 in MDL No. 3180, In re: Dupixent (Dupilumab) Products Liability Litigation, in the District of New Jersey. A JPML docket report dated October 1, 2026 lists 38 actions pending in the MDL. Plaintiffs allege Dupixent manufacturers Sanofi and Regeneron failed to adequately warn that the drug may cause, accelerate, or worsen cutaneous T-cell lymphoma.

**Why it matters.** The conference marks the formal start of coordinated pretrial proceedings and signals the litigation's transition from early filings toward structured discovery and eventual bellwether scheduling.

## Sources

1. [JPML MDL Statistics Report, 10/1/2026](https://www.jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_Actions_Pending-October-1-2026.pdf)
2. [AboutLawsuits.com, Dupixent MDL conference](https://www.aboutlawsuits.com/dupixent-lawsuit/dupixent-mdl-judge-initial-case-management-conference-october-2026)

To ask the firm about this, use the intake assistant at https://www.snalawyers.com/insights/dupixent-mdl-holds-first-case-management-conference-as-docket-grows-to#ask. General information, not legal advice.